J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor J INTS BIO has revealed groundbreaking clinical research on JIN-A02, a fourth-generation EGFR inhibitor, offering new hope for patients with lung cancer.

J INTS BIO Unveils Promising Results for JIN-A02, a Fourth-Generation EGFR Inhibitor #South_Korea #Seoul #J_INTS_BIO #EGFR_Inhibitor #JIN-A02

J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025 J INTS BIO has shared interim findings from its clinical trial for JIN-A02, a fourth-generation EGFR-TKI, showing notable anti-tumor activity.

J INTS BIO Unveils Promising Clinical Results of JIN-A02 at ASCO 2025 #South_Korea #Seoul #J_INTS_BIO #JIN-A02 #EGFR-TKI

Advancing Brain Tumor Treatments: J INTS BIO Unveils 'JIN-001' with MD Anderson J INTS BIO and MD Anderson reveal outcomes from their collaboration on 'JIN-001,' a new therapy enhancing standard brain tumor treatments.

Advancing Brain Tumor Treatments: J INTS BIO Unveils 'JIN-001' with MD Anderson #South_Korea #Seoul #J_INTS_BIO #MD_Anderson #JIN-001